Vasogen Inc.

Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade(TM) in the European Union

    Toronto, Canada (ots/PRNewswire) -

    - Vasogen to Host Conference Call Today at 9:00 a.m. (ET)

    Vasogen Inc. (NASDAQ:VSGND; TSX:VAS) today announced a collaboration with  Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European  pharmaceutical and medical devices company, to commercialize Vasogen's Celacade(TM) technology for the treatment of chronic heart failure in the European Union and in certain Latin American countries. Under the agreement, Vasogen will receive 45% of Celacade revenues generated by Ferrer, as set out below, for a period five years from the date of first commercial sale on a country-specific basis, and will receive 42% of such revenues thereafter. Ferrer will be responsible for the costs associated with the launch and marketing of Celacade in Europe and certain Latin American countries. Vasogen will also receive milestone payments based on Ferrer's achievement of first commercial sales of Celacade on a country-specific  basis, and on reaching pre-specified sales thresholds. Chronic heart failure is a leading cause of morbidity and mortality throughout the western world and affects over 6 million people in Europe alone.

    "Chronic heart failure is a major healthcare challenge in the industrialized world and this agreement represents a significant economic opportunity for our Celacade technology - a first-in-class therapeutic entrant," commented Terry Gregg, President, Chief Executive Officer, and Chairman of Vasogen. "Given Grupo Ferrer's proven ability to successfully introduce new healthcare technologies into the large markets of Europe and Latin America, we are extremely excited about this partnership and look forward to the initial commercialization of Celacade later this year."

    "Having followed the development of Celacade for several years, we are very enthusiastic about the opportunity for Grupo Ferrer to market this new immuno-modulatory strategy to the cardiology community of Europe and Latin America," stated Dr. Carlos de Lecea, Vice President International & Business Development at Ferrer. "Celacade offers cardiologists an entirely new way to target the pathological inflammatory processes of heart failure not addressed by available therapies, and given the magnitude of the heart failure problem, we see a large economic opportunity for both Vasogen and Ferrer."

    Vasogen will host a conference call and web cast today (Wednesday, April 18, 2007) at 9:00 a.m. ET, to discuss the collaboration.

    Interested parties are invited to participate by connecting 10 minutes prior to the start of the call to one of the following:

@@start.t1@@      Audio Web Cast:                                                                 www.vasogen.com
      Direct Dial:                                                                          416-695-6130
      Toll-free:                                                                          1-888-789-0150
      A re-broadcast of the conference call may be accessed by:
      Audio Web Cast                                                                  www.vasogen.com
      Direct Dial:                                                                          416-695-6034
      Toll-free                                                                            1-877-605-9320
      Pin Code:                                                3259 followed by the number sign@@end@@

    Vasogen/Ferrer Collaboration:

    Under the agreement, Ferrer will have the exclusive rights to market Celacade for the treatment of chronic heart failure and other cardiovascular conditions in specified countries of Europe, including Germany, Spain, Portugal, France, and Italy, and certain countries in Latin America,  Including Mexico, Brazil, Argentina, and Venezuela. Vasogen has already  Received European Union (EU) regulatory approval as a medical device under  the CE Mark, which enables marketing of Celacade for the treatment of chronic heart failure in the 27 member countries of the European Union. Ferrer has also acquired the right of first negotiation with respect to the remaining  countries of the EU. Under the agreement, the commercial launch strategy for  Celacade in Europe will involve an initial commercialization phase during which Ferrer will target key opinion leaders in the major markets of Europe  to ensure support for expanded use of Celacade within the broader cardiology  community. Ferrer expects to commence the initial commercialization phase in  the second half of 2007. Following the completion of the initial  commercialization phase, Vasogen will receive 45% of Celacade revenues  generated by Ferrer through the sale of Celacade single-use disposable  cartridges, one of which is required for the delivery of each Celacade  monthly treatment. After a period five years from the date of the first  commercial sale on a country-specific basis, Vasogen's share of the revenues will be 42%. Also under the terms of the agreement, Ferrer will be  financially responsible for all costs associated with the launch and  marketing of Celacade. Vasogen will receive milestone payments based on Ferrer's achievement of first commercial sales of Celacade on a country- specific basis, and on reaching pre-specified sales thresholds.

    About Celacade:

    Therapy utilizing the Celacade technology targets the inflammation underlying chronic heart failure and other cardiovascular diseases. Inflammation is a normal response of the immune system to cellular injury caused by infection, trauma, or other stimuli. During the inflammatory process, immune cells release a number of factors, including cytokines - potent chemical messengers that modulate inflammation and facilitate the healing process. While this inflammatory process is usually self-limiting, it can persist, become chronic, and lead to a number of serious medical conditions.

    During a brief outpatient procedure, a small sample of a patient's blood is drawn into Vasogen's Celacade single-use disposable cartridge and exposed to controlled oxidative stress utilizing Vasogen's proprietary Celacade medical device technology. Oxidative stress is a factor known to initiate apoptosis, a physiologic process that is inherently anti-inflammatory. The treated blood is then administered to the same patient intramuscularly. An initial course of treatment comprising three consecutive outpatient  procedures is administered over a two-week period, and treatments are  continued once per month thereafter.

    About Grupo Ferrer Internacional, S.A.:

    Grupo Ferrer Internacional is a privately held European research and commercial development based pharmacochemical and medical devices company headquartered in Barcelona, Spain. Ferrer operates today in over 60 countries with the overall aim to improve people's health and quality of life. Based on its policy of continuous expansion throughout the world, Ferrer has established strong industrial and commercial operations in Europe and has extensive commercial experience in Latin America, Africa, and in the Middle and Far East. Ferrer has licensing, distribution, and marketing agreements with large multinational pharmaceutical companies, as well as mid-size firms including AstraZeneca, Astellas, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Roche, Sanofi-Aventis, Solvay, Cephalon, United Therapeutics, and The Medicines Co., among others.

    In addition to its commercial operations, Grupo Ferrer operates pharmaceutical research and development facilities in Barcelona, Spain and Alsdorf, Germany. The research facilities in Barcelona manage all aspects of drug development from concept through to clinical development and product registration. The Alsdorf facility is specialized in new applications of pharmaceutical technology. Grupo Ferrer also has established research collaborations with a large number of pharmaceutical companies and universities throughout the world.

    About Vasogen:

    Vasogen is a biotechnology company engaged in the research and Commercial development of therapies designed to target the destructive  Inflammatory process associated with the development and progression of  cardiovascular and neurodegenerative disorders. The Company's lead product,  the Celacade(TM) technology, is designed to activate the immune response to  apoptosis - an important physiological process that regulates inflammation.  Celacade is in late-stage clinical development for the treatment of chronic  heart failure and has received European regulatory approval under the CE Mark  for this indication. Vasogen is also developing a new class of drugs for the  treatment of certain neuro-inflammatory disorders and is preparing to advance  VP025, the lead drug candidate from this new class, into phase II evelopment.

    Certain statements contained in this press release, the upcoming conference call and web cast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, summary statements relating to results of the ACCLAIM trial in patients with chronic heart failure, plans to advance the development of Celacade(TM), plans to fund our current activities, statements concerning our partnering activities and health regulatory submissions, strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management. In some cases, you can  identify forward-looking statements by terminology such as "may", "will",  "should", "expects", "plans", "anticipates", "believes", "estimated",  "predicts", "potential", "continue", "intends", "could", or the negative of  such terms or other comparable terminology. We made a number of assumptions  in the preparation of these forward-looking statements, including assumptions  about the nature, size and accessibility of the market for Celacade in the  treatment of chronic heart failure, particularly in Europe, the regulatory  approval process leading to commercialization and the availability of capital  on acceptable terms to pursue the development of Celacade, and the  feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and  uncertainties that could cause actual results, future circumstances or events  to differ materially from those projected in the forward-looking statements.  These risks include, but are not limited to, the outcome of further analysis  of the ACCLAIM trial results, the requirement or election to conduct  additional clinical trials, delays or setbacks in the regulatory approval  process, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other  factors on capital availability, the potential dilutive effects of any  financing, risks associated with the outcomes of our preclinical and clinical  research and development programs, the adequacy, timing and results of our  clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the  strength of intellectual property, reliance on subcontractors and key  personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or  other filings with the Canadian and U.S. securities commissions or other  securities regulatory bodies. Additional risks and uncertainties relating to  our Company and our business can be found in the "Risk Factors" section of  our Annual Information Form and Form 20-F for the year ended November 30,  2006, as well as in our later public filings. The forward-looking statements  are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise  any forward-looking statements, whether as a result of new information,  future events or otherwise. Unless otherwise indicated, numerical values  indicating the statistical significance ("p-values") of results included in  this document are based on analyses that do not account for endpoint  multiplicity.

    www.vasogen.com

ots Originaltext: Vasogen Inc
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
For further information: Glenn Neumann, Investor Relations, 2505
Meadowvale Blvd., Mississauga, ON, Canada, L5N 5S2, tel:
+1-905-817-2004, fax: +1-905-569-9231, investor@vasogen.com



Weitere Meldungen: Vasogen Inc.

Das könnte Sie auch interessieren: